These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32667948)

  • 1. Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV.
    Theobald SJ; Kreer C; Khailaie S; Bonifacius A; Eiz-Vesper B; Figueiredo C; Mach M; Backovic M; Ballmaier M; Koenig J; Olbrich H; Schneider A; Volk V; Danisch S; Gieselmann L; Ercanoglu MS; Messerle M; Kaisenberg CV; Witte T; Klawonn F; Meyer-Hermann M; Klein F; Stripecke R
    PLoS Pathog; 2020 Jul; 16(7):e1008560. PubMed ID: 32667948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
    Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.
    Bootz A; Karbach A; Spindler J; Kropff B; Reuter N; Sticht H; Winkler TH; Britt WJ; Mach M
    PLoS Pathog; 2017 Aug; 13(8):e1006601. PubMed ID: 28854233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
    Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
    Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Strain-Specific Neutralizing Epitope on Glycoprotein H of Human Cytomegalovirus.
    Thomas M; Kropff B; Schneider A; Winkler TH; Görzer I; Sticht H; Britt WJ; Mach M; Reuter N
    J Virol; 2021 Aug; 95(18):e0065721. PubMed ID: 34160252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.
    Pötzsch S; Spindler N; Wiegers AK; Fisch T; Rücker P; Sticht H; Grieb N; Baroti T; Weisel F; Stamminger T; Martin-Parras L; Mach M; Winkler TH
    PLoS Pathog; 2011 Aug; 7(8):e1002172. PubMed ID: 21852946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant Antiviral CD8
    Pardieck IN; van Duikeren S; Veerkamp DMB; Brasem DJ; Redeker A; van Bergen J; Han W; Ossendorp F; Zondag G; Arens R
    Front Immunol; 2022; 13():680559. PubMed ID: 35154089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited Effector Memory B-Cell Response to Envelope Glycoprotein B During Primary Human Cytomegalovirus Infection.
    Dauby N; Sartori D; Kummert C; Lecomte S; Haelterman E; Delforge ML; Donner C; Mach M; Marchant A
    J Infect Dis; 2016 May; 213(10):1642-50. PubMed ID: 26715677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
    Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
    Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients.
    Lilleri D; Zelini P; Fornara C; Zavaglio F; Rampino T; Perez L; Gabanti E; Gerna G
    J Med Virol; 2018 Oct; 90(10):1620-1628. PubMed ID: 29797330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.
    Kauvar LM; Liu K; Park M; DeChene N; Stephenson R; Tenorio E; Ellsworth SL; Tabata T; Petitt M; Tsuge M; Fang-Hoover J; Adler SP; Cui X; McVoy MA; Pereira L
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1558-68. PubMed ID: 25534746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Cytomegalovirus (HCMV)-Specific CD4
    Jackson SE; Sedikides GX; Mason GM; Okecha G; Wills MR
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28053099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
    Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
    Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH/gL/pUL128L and Trimer gH/gL/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation.
    Gerna G; Percivalle E; Perez L; Lanzavecchia A; Lilleri D
    J Virol; 2016 Jul; 90(14):6216-6223. PubMed ID: 27122579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    Liu Y; Freed DC; Li L; Tang A; Li F; Murray EM; Adler SP; McVoy MA; Rupp RE; Barrett D; Ye X; Zhang N; Beck K; Culp T; Das R; Song L; Vora K; Zhu H; Wang D; Espeseth AS; An Z; Musey L; Fu TM
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.
    Wussow F; Chiuppesi F; Martinez J; Campo J; Johnson E; Flechsig C; Newell M; Tran E; Ortiz J; La Rosa C; Herrmann A; Longmate J; Chakraborty R; Barry PA; Diamond DJ
    PLoS Pathog; 2014 Nov; 10(11):e1004524. PubMed ID: 25412505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.